Pelthos Therapeutics Inc. PTHS

22.19 (0.21) (0.94%) as of 25 Sep
Market cap
$85.8M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
2,161.07% (881.53%) (239.55%) (82.99%)

+8 more TTM periods

ROA
(125.04%) (90.81%) (65.75%) (36.68%)
ROIC
(82.34%) (51.99%) (38.76%) (31.61%)
Return on Tangible Assets
(214.49%) (122.76%) (117.07%) (67.05%)
Average Days of Receivables
122.07 0.00 0.00 0.00
Free Cash Flow per Share
(12.03) (10.68) (12.01) (5.56)
Free Cash Flow
(42.60) (35.38) (22.59) (17.01)
Capital Expenditures
(0.29) (0.29) — —
Piotroski F-Score
1.00 4.00 4.00 4.00
Other line items
Cash ROIC
(45.50%) (29.99%) (25.57%) (23.46%)
Accounts Receivable Turnover
0.00 — — —
Accounts Payable Turnover
1.71 0.00 0.00 0.00
Inventory Turnover
0.00 — — —
Average Days of Payables
230.43 0.00 0.00 0.00
Days of Inventory on Hand
845.35 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
3.01% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
200.61% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
21.31% 0.00% 0.00% 0.00%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.49 0.53 0.52 0.72
Depreciation/Fixed assets
0.65 0.46 0.27 0.15
Capex/Depreciation
(0.05) (0.07) 0.00 0.00
Revenue per Share
12.23 0.00 0.00 0.00
Operating CF per Share
(11.95) (10.59) (12.01) (5.56)
Capex per Share
(0.08) (0.09) 0.00 0.00
Capex to Sales
0.01 0.00 — —
Net Profit Margin
(199.50%) 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates